AbbVie and Genmab Report 51% Reduction in Progression With Epcoritamab Plus R-CHOP in Diffuse Large B-cell Lymphoma
AbbVie and Genmab reported Phase 3 trial results showing a 51% reduction in disease progression or death for epcoritamab plus R-CHOP in diffuse large B-cell lymphoma (DLBCL) patients with IPI scores of 2-5. The combination therapy met its primary endpoint, improving progression-free survival. The companies plan to discuss the findings with regulators. Epcoritamab is an investigational bispecific antibody.
How this was made
The 30-second read
Why it matters
The data represents a material clinical milestone that could drive near‑term stock moves and long‑term pipeline value.
Market read
First report of significant Phase 3 efficacy data for a bispecific antibody, likely to influence biotech equities and sector sentiment.
What to watch
Potential regulatory hurdles and competition from other CD20‑targeted bispecifics could temper upside.
Background
The article reports first‑time topline results from the Phase 3 EPCORE DLBCL-2 trial, a pivotal study for epcoritamab in newly diagnosed diffuse large B‑cell lymphoma.
Ticker impact
AbbVie announced positive Phase 3 EPCORE DLBCL-2 trial results showing a 51% reduction in progression risk for DLBCL patients.
upward pressure as the market prices in the significant efficacy improvement.
Phase 3 data with a hazard ratio of 0.49 is material for a large oncology pipeline.
Market effects
Strengthens the oncology/biotech sector outlook, especially for bispecific antibody programs.
Positive impact on US and European biotech markets where AbbVie and Genmab are listed.
Adds confidence to global investors tracking cancer therapy pipelines.
Counterpoint
Skeptics may question the lack of overall survival data and safety profile before valuation upgrades.
Key entities
- CompanyAbbVie
US‑based biopharma developing epcoritamab.
- CompanyGenmab
Danish biotech partner co‑developing epcoritamab.
